148 related articles for article (PubMed ID: 37790750)
1. Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells.
Guzzetti C; Corno C; Vergani E; Mirra L; Ciusani E; Rodolfo M; Perego P; Beretta GL
Front Oncol; 2023; 13():1182853. PubMed ID: 37790750
[TBL] [Abstract][Full Text] [Related]
2. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
[TBL] [Abstract][Full Text] [Related]
3. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.
Rohrbeck L; Gong JN; Lee EF; Kueh AJ; Behren A; Tai L; Lessene G; Huang DC; Fairlie WD; Strasser A; Herold MJ
Cell Death Differ; 2016 Dec; 23(12):2054-2062. PubMed ID: 27689874
[TBL] [Abstract][Full Text] [Related]
5. Functional analysis of the emerging roles for the KISS1/KISS1R signaling pathway in cancer metastasis.
Li Z; Liu J; Inuzuka H; Wei W
J Genet Genomics; 2022 Mar; 49(3):181-184. PubMed ID: 34767970
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2.
Wu T; Li C; Zhou C; Niu X; Li G; Zhou Y; Gu X; Cui H
Cell Biol Toxicol; 2023 Oct; 39(5):2381-2399. PubMed ID: 35648318
[TBL] [Abstract][Full Text] [Related]
7. Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells.
Martin S; Dudek-Perić AM; Maes H; Garg AD; Gabrysiak M; Demirsoy S; Swinnen JV; Agostinis P
Biochem Pharmacol; 2015 Feb; 93(3):290-304. PubMed ID: 25529535
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ
Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758
[TBL] [Abstract][Full Text] [Related]
9. Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy.
Nash KT; Phadke PA; Navenot JM; Hurst DR; Accavitti-Loper MA; Sztul E; Vaidya KS; Frost AR; Kappes JC; Peiper SC; Welch DR
J Natl Cancer Inst; 2007 Feb; 99(4):309-21. PubMed ID: 17312308
[TBL] [Abstract][Full Text] [Related]
10. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
[TBL] [Abstract][Full Text] [Related]
11. KiSS1 in regulation of metastasis and response to antitumor drugs.
Corno C; Perego P
Drug Resist Updat; 2019 Jan; 42():12-21. PubMed ID: 30776659
[TBL] [Abstract][Full Text] [Related]
12. Expression of functional KISS1 and KISS1R system is altered in human pituitary adenomas: evidence for apoptotic action of kisspeptin-10.
Martínez-Fuentes AJ; Molina M; Vázquez-Martínez R; Gahete MD; Jiménez-Reina L; Moreno-Fernández J; Benito-López P; Quintero A; de la Riva A; Diéguez C; Soto A; Leal-Cerro A; Resmini E; Webb SM; Zatelli MC; degli Uberti EC; Malagón MM; Luque RM; Castaño JP
Eur J Endocrinol; 2011 Mar; 164(3):355-62. PubMed ID: 21169415
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
Xiao J; Egger ME; McMasters KM; Hao H
BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
[TBL] [Abstract][Full Text] [Related]
14. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
17. BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.
Paoluzzi L; Hanniford D; Sokolova E; Osman I; Darvishian F; Wang J; Bradner JE; Hernando E
Cancer Med; 2016 Jun; 5(6):1183-93. PubMed ID: 27169980
[TBL] [Abstract][Full Text] [Related]
18.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
19. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.
Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS
Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
Luo H; Umebayashi M; Doi K; Morisaki T; Shirasawa S; Tsunoda T
Anticancer Res; 2016 Jul; 36(7):3585-9. PubMed ID: 27354627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]